SOTIO initiates first-in-human clinical trial with IL-15 superagonist SO-C101
SOTIO and Cytune Pharma, members of the PPF Group, announce today the first dosing of cancer patients with SO-C101, a superagonist fusion protein of interleukin IL-15. The phase I/Ib study (SC103) will evaluate the safety and preliminary efficacy of SO-C101 in patients with selected advanced/metastatic solid tumors.
The first patient was treated with SO-C101 at the Institute Gustave Roussy (France). The SC103 clinical trial will also enrol patients in the Vall d’Hebron cancer center (Spain) and, subject to obtaining all the necessary approvals, at the Yale Cancer Center in New Haven, CT and MD Anderson Cancer Center in Houston, TX. Cytune Pharma is responsible for the clinical development of SO-C101, SOTIO is sponsor of the SC103 clinical trial.
Aurélien Marabelle, M.D., Ph.D., coordinating investigator of the phase I/Ib trial said: “I am very pleased that our medical center has enrolled the first patient in this important clinical trial. We believe that SO-C101 has the potential to make a life-changing difference to many patients with difficult-to-treat forms of cancer. I am looking forward to further advancing this innovative therapy.“
“SO-C101 is a very innovative approach which has been validated for its efficacy and safety in preclinical experiments. Since SO-C101 is an ideal combination partner for checkpoint inhibitors, monoclonal antibodies and other well established therapies, the planning for additional combination trials is already ongoing,” said Radek Spisek, M.D., Ph.D., CEO of SOTIO.
“I’m excited that after 12 years of research and development at Cytune Pharma, which was based on previous research from INSERM and the University of Nantes and supported by Bpifrance and Atlanpole Biotherapies, our invention has now entered the clinical development phase. I hope that SO-C101 will become a treatment for cancer patients in the future,” adds David Bechard, Ph.D., President and COO of Cytune Pharma.
Description of clinical trial
SC103 (Eudra CT: 2012-002814-38): A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in selected patients with advanced/metastatic solid tumors. SOTIO received a positive decision allowing launch of SC103 clinical trial within the EU Voluntary Harmonisation Procedure (VHP) in February 2019.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Research Reveals Disparity in Expectations in PSD2 Awareness Between European Retailers and Shoppers15.10.2019 23:01:00 CEST | Press release
Leading eCommerce solution provider, Riskified, announced today a new European-wide study revealing a staggering disparity between retailers’ and online shoppers’ awareness of the Payment Services Directive 2 (PSD2). The survey of 2,000 consumers and 200 retailers, with respondents evenly split across the UK, Germany, France, and Spain, found that nine out of ten retailers (88%) believe consumers are ‘somewhat’ or ‘very aware’ of PSD2. However, more than three-quarters (76%) of consumers report that they haven’t even heard of it. The implementation of the regulation is set to add new security measures for all online transactions over €30. This means that for most online transactions, consumers will need to undergo multi-factor authentication to verify their identity, such as entering a code received via their mobile phone, providing biometric data such as a fingerprint, or other forms of authentication. Commenting on the findings, Eido Gal, Co-Founder and CEO, Riskified, said: “Fraud i
Dubai World Challenge for Self-Driving Transport Winners Announced for Prizes Worth USD 5.1 Million15.10.2019 20:12:00 CEST | Press release
Dubai World Congress for Self-Driving Transport; organised by Roads and Transport Authority (RTA) Dubai on 15th and 16th October 2019 has attracted more than 700 technology leaders and innovators as well as 3000 visitors of the accompanying exhibition. The congress focuses on cutting-edge technologies, besides discussing and developing a general legislative structure for autonomous transport. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015006107/en/ Winners of the Dubai World Self-Driving Transport Challenge (Photo: AETOSWire) The event is part of RTA’s efforts in support of the strategy unleashed by HH Sheikh Mohammed bin Rashid Al Maktoum, Vice-President and Prime Minister of the UAE and Ruler of Dubai, to make 25% of all trips in Dubai smart and driverless by 2030. The congress attracted 80 international experts, including five keynote speakers, who will be taking part in 40 lectures and 39 technical workshops. The
Norwegian Video Trailblazers Create Neat to Change the Game with Zoom15.10.2019 16:00:00 CEST | Press release
Today at Zoomtopia 2019, Neat, a trailblazing Norwegian startup, launched its portfolio of meeting room systems designed for Zoom Video Communications, Inc. (NASDAQ: ZM). Neat's video devices are built from the ground up and developed in close partnership with Zoom. The systems are as easy to buy and set up as any consumer product, while providing complete enterprise-grade management and security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005773/en/ Zoom Video Systems by Neat (Photo: Business Wire) Neat's systems embrace breakthrough technology to eliminate the complexities of video in meeting rooms, along with simplifying the entire user experience. The company has reimagined every aspect of the Zoom Rooms customer journey, including how people buy, install, use and manage its products. Based in Oslo, Norway (aka "Video Valley”), Neat has offices in the US, UK, and Taiwan. Although the company is new, Neat’s team
The success story of the Aloe Vera Drinking Gel by LR Health & Beauty continues15.10.2019 15:23:00 CEST | Press release
LR Health & Beauty is further expanding its Aloe vera product portfolio with its new product Aloe Vera Drinking Gel Immune Plus. The development and manufacturing of Aloe vera products has been one of the core competences of the global direct sales company for more than 17 years. True to the motto "More quality for your life", LR now presents Immune Plus as a premium product to support the immune system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005834/en/ The success story of the Aloe Vera Drinking Gel by LR Health & Beauty continues (Photo: Business Wire) The Aloe Vera Drinking Gels have been LR’s bestsellers since 2002. They offer support in different life situations and are available in various flavors. The special feature of Immune Plus is the synergetic interaction of the ingredients – 85% Aloe vera leaf gel with 8% honey, 6% ginger juice and lemon juice, enriched with vitamin C, zinc and selenium – which ha
International Experts Invited to Attend Riyadh’s Sustainable City Symposium15.10.2019 14:49:00 CEST | Press release
The Royal Commission for Riyadh City (RCRC), formally known as Riyadh Development Authority, has invited international experts to participate in a Symposium setting out the next chapter in Riyadh’s development as a sustainable city, one that will enhance the lives of its citizens, while finding solutions to the difficult challenges facing all cities across the world today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005797/en/ International Experts Invited to Attend Riyadh’s Sustainable City Symposium (Photo: AETOSWire) ‘Riyadh’s Sustainable Future’ Symposium will take place on November 12 & 13, 2019 in Riyadh and will focus on four of the capital’s most ambitious projects, launched by King Salman bin Abdulaziz Al Saud, and stemming from an initiative from Prince Mohammed bin Salman bin Abdulaziz Al Saud, the Crown Prince. These four projects are transformative and will help to establish Riyadh as one of the most li
Mundipharma presents wealth of data for Penthrox®▼ (methoxyflurane) at EUSEM Congress, demonstrating superiority compared to standard of care in trauma pain in adults15.10.2019 14:05:00 CEST | Press release
FOR EUROPEAN MEDICAL AND TRADE MEDIA ONLY Mundipharma presents new data for the inhaled analgesic Penthrox ® (methoxyflurane)6 at the European Society for Emergency Medicine (EUSEM) Congress 2019, from 12–16 October. Five abstracts are being presented, advancing the understanding of the use of methoxyflurane in the treatment of moderate to severe trauma-related pain for adults in emergency settings in Europe: MEDITA Study1 #18647: the first study to directly compare the effectiveness of methoxyflurane to standard analgesic treatment (SAT) – IV morphine for severe pain, and IV paracetamol or ketoprofen for moderate trauma pain in Italy. Methoxyflurane was superior to IV morphine (severe pain) and IV paracetamol or IV ketoprofen (moderate pain) for the primary endpoint, defined as the change in pain intensity over the first 10 minutes (overall adjusted mean treatment difference: 5.94mm; 95% CI: 8.83, 3.06mm) following pain treatment administration.1 Methoxyflurane was rated as ‘excellent